Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Dec 26, 2022 6:04am
111 Views
Post# 35191808

RE:Midatech

RE:Midatech
prophetoffactz wrote:
From our team at #MidatechPharma, we would like to wish all of you a very Merry Christmas and a Happy 2023! Our office will be closed until January 3rd. For any urgent matters, please contact ir@midatechpharma.com. We look forward to the successes the New Year will bring!





What could one success in the New Year be? During Midatech's merger presentation the CEO said the company is working on a number of preclinical experiments right now for delivery into tumor with Q-Sphera. He says so if you can imagine delivering drug directly into a tumor for extended periods of time: a) you could avoid systemic toxicities that come with many chemo drugs with less frequent dosing; b) you could probably achieve a higher average dose in the tumor.They have some interesting experiments that they should be able to publish in the early part of the year he says. 
<< Previous
Bullboard Posts
Next >>